Details for Patent: 10,251,894
✉ Email this page to a colleague
Which drugs does patent 10,251,894 protect, and when does it expire?
Patent 10,251,894 protects ZULRESSO and is included in one NDA.
This patent has fifteen patent family members in seven countries.
Summary for Patent: 10,251,894
| Title: | Anticonvulsant activity of steroids |
| Abstract: | The present invention relates to methods of preventing, inhibiting, delaying, and/or mitigating seizures by administration of a steroid, e.g., a neurosteroid, e.g., allopregnanolone. |
| Inventor(s): | Rogawski; Michael A. (Sacramento, CA), Zolkowska; Dorota (Davis, CA) |
| Assignee: | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) |
| Application Number: | 15/917,245 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 10,251,894
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sage Therap | ZULRESSO | brexanolone | SOLUTION;INTRAVENOUS | 211371-001 | Jun 17, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING POSTPARTUM DEPRESSION | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,251,894
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013352141 | ⤷ Sign Up | |||
| Australia | 2018204865 | ⤷ Sign Up | |||
| Australia | 2020201919 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
